

Development of a stability-indicating assay method and study of the physico-chemical stability of Etoposide phosphate in 0.9% sodium chloride solution

> Gons C., Roquefeuil L., Ratiney R., Cotteret C., Schweitzer-Chaput A. Pharmacy Department, Necker-Enfants Malades hospital, AP-HP, Paris-Cité university, Paris, France



COM24-18346

## Introduction

Macrophage activation syndrome (MAS) is a rare complication of certain haemopathies characterised by tissue infiltration by activated macrophages. The standard treatment consists of intravenous administration of Etoposide phosphate (EP) at a dose of 150 mg/m<sup>2</sup>. To manage this therapeutic emergency, EP must be available without delay. One way of meeting this need is to set up standard doses.



 $\odot$ T

The stability of an injectable solution of EP diluted in a 0.9% sodium chloride polyolefin bag at 1 mg/mL has been demonstrated for 60 days at room temperature and at +4°C. This stability period is

compatible with the implementation of standard doses, available at any time for the management of MAS.